NCT03125473View on ClinicalTrials.gov

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 7, 2017

Primary Completion Date

July 1, 2017

Study Completion Date

May 6, 2018

Conditions
Norovirus Gastroenteritis
Interventions
BIOLOGICAL

VXA-G1.1-NN Oral Vaccine

The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.

Trial Locations (1)

68502

Celerion, Inc., Lincoln

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT03125473 - Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers | Biotech Hunter | Biotech Hunter